MRD

13 registered clinical trials studyying MRD — 9 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	Molecular Surveillance In Early Breast Cancer Using The Tumor-Informed ctDNA Assay Myriad Genetics Precise MRD NCT07475923	M.D. Anderson Cancer Center	—
Not Yet Recruiting	Minimal Residual Disease Used in Predicting Therapeutic Efficacy in Metastatic Hormone-sensitive Prostate Canc NCT07112612	Anhui Medical University	—
Enrolling By Invitation	Based on ctDNA-MRD Guided Adjuvant Treatment Escalation After Definitive Chemoradiotherapy for Unresectable Lo NCT07371247	The First Affiliated Hospital with Nanjing Medical University	EARLY_Phase 1
Not Yet Recruiting	A Study of Tumor-Agnostic MRD Detection in Stage III Colorectal Cancer NCT07254156	Sun Yat-sen University	—
Recruiting	Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung) NCT07120698	Guangdong Association of Clinical Trials	Phase 2
Not Yet Recruiting	A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis NCT07215494	Peking University First Hospital	N/A
Recruiting	Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection NCT06409702	The First Affiliated Hospital of Soochow University	Phase 4
Recruiting	Observational Clinical Study on Role of MRD in Predicting Local Therapy in Oligometastatic Breast Cancer NCT06918262	The First Hospital of Jilin University	—
Recruiting	Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results NCT05736978	Shanghai Tong Ren Hospital	Phase 2
Recruiting	Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC NCT05536505	Guangdong Association of Clinical Trials	Phase 2
Unknown	Risk-stratified Therapy Based on Molecular Cytogenetic Aberration and Treatment Response in AML NCT03620955	Nanfang Hospital, Southern Medical University	—
Unknown	A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK NCT03971305	Sun Yat-sen University	—
Unknown	Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT NCT02872662	Nordic MDS Group	—